Here are three things to know:
- The acquisition deal includes an upfront payment of approximately $360 million for the 90% of SoniVie not already owned by Boston Scientific, with an additional $180 million contingent on regulatory milestones, according to a March 1 news release from the company.
- The TIVUS system uses ultrasound energy to target nerve activity linked to hypertension, potentially offering an alternative or adjunct to existing blood pressure treatments.
- The acquisition is expected to close in the first half of 2025 and is pending regulatory approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.